DNA topoisomerase II inhibitors.
D000677:Amsacrine / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002273:Carcinogens / Q000009:adverse effects* / Q000737:chemistry; D004195:Disease Models, Animal; D005047:Etoposide / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007408:Intestinal Absorption; D008942:Mitoxantrone / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012107:Research Design; D012307:Risk Factors; D013713:Teniposide / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014018:Tissue Distribution; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D002273:Carcinogens; D019384:Nucleic Acid Synthesis Inhibitors; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D005047:Etoposide; D013713:Teniposide; D008942:Mitoxantrone